See the DrugPatentWatch profile for uptravi
What are Oral Prostacyclin Analogues?
Oral prostacyclin analogues are a class of medications designed to mimic the effects of prostacyclin, a naturally occurring substance in the body that helps relax blood vessels and prevent blood clots. These drugs are primarily used to treat pulmonary arterial hypertension (PAH), a severe condition where blood pressure in the arteries of the lungs is dangerously high [1].
Uptravi and Oral Prostacyclin Analogues
Uptravi (selexipag) is an oral prostacyclin analogue. It is prescribed to treat pulmonary arterial hypertension in adults [1]. Uptravi works by selectively targeting the prostacyclin receptor (IP receptor) in the blood vessels of the lungs, leading to vasodilation (widening of blood vessels) and a reduction in blood pressure [2].
How Does Uptravi Work?
Uptravi functions as a prostacyclin receptor (IP receptor) agonist. By activating this receptor, it promotes vasodilation in the pulmonary arteries. This mechanism helps to lower the pressure in the lung's arteries and improve the heart's ability to pump blood [2].
When Does Uptravi Patent Exclusivity Expire?
The patent exclusivity for selexipag, the active ingredient in Uptravi, is a complex issue involving multiple patents with varying expiry dates. According to DrugPatentWatch.com, the earliest expected patent expiry for selexipag is in 2031 [3]. However, the actual market exclusivity can be influenced by further patent filings, legal challenges, and regulatory exclusivities.
Why Might Companies Challenge Selexipag Patents?
Pharmaceutical companies often challenge drug patents to pave the way for the development and introduction of generic versions of a medication. Generic drugs, once approved, can offer a more affordable alternative to brand-name medications, increasing patient access and reducing healthcare costs. Challenges can stem from arguments related to patent validity, obviousness, or the scope of patent claims [3].
Can Biosimilars Enter Before Patent Expiry?
For small molecule drugs like Uptravi, the term used is "generics" rather than "biosimilars." Biosimilars apply to biologic drugs. Generic versions of Uptravi can only enter the market after the relevant patents expire or are invalidated through legal proceedings [3].
What are the Side Effects of Uptravi?
Common side effects associated with Uptravi include headache, diarrhea, nausea, vomiting, jaw pain, muscle pain, and pain in extremity [1]. Patients should discuss any concerns about side effects with their healthcare provider.
How Does Uptravi Compare to Other PAH Treatments?
Uptravi is one of several treatment options for PAH. Other medications may include endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and inhaled or intravenous prostacyclin therapies. The choice of treatment depends on the severity of the PAH, individual patient characteristics, and the treatment goals [4].
What is the Price of Uptravi?
The price of Uptravi can vary significantly depending on factors such as insurance coverage, geographic location, and pharmacy. Patients may need to consult with their insurance provider or the manufacturer for specific pricing information [1].
Sources:
[1] https://www.uptravi.com/
[2] https://www.drugpatentwatch.com/drugs/selexipag
[3] https://www.drugpatentwatch.com/
[4] https://www.mayoclinic.org/diseases-conditions/pulmonary-hypertension/diagnosis-treatment/drc-20351440